BRPI0418212A - composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade - Google Patents

composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade

Info

Publication number
BRPI0418212A
BRPI0418212A BRPI0418212-0A BRPI0418212A BRPI0418212A BR PI0418212 A BRPI0418212 A BR PI0418212A BR PI0418212 A BRPI0418212 A BR PI0418212A BR PI0418212 A BRPI0418212 A BR PI0418212A
Authority
BR
Brazil
Prior art keywords
obesity
diabetes
pharmaceutically acceptable
salt
nitrogen
Prior art date
Application number
BRPI0418212-0A
Other languages
English (en)
Inventor
Katsumasa Nonoshita
Yoshio Ogino
Makoto Ishikawa
Fumiko Sakai
Hiroshi Nakashima
Yoshikazu Nagae
Daisuke Tsukahara
Keisuke Arakawa
Teruyuki Nishimura
Jun-Ichi Eiki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of BRPI0418212A publication Critical patent/BRPI0418212A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"COMPOSTO OU UM SAL DESTE FARMACEUTICAMENTE ACEITáVEL, ATIVADOR DA GLICOCINASE, E, MEDICAMENTOS PARA A TERAPIA E/OU PREVENçãO DA DIABETE, E DA OBESIDADE". Um ativador da glicocinase; um agente terapêutico e/ou preventivo para a diabete ou um agente terapêutico e/ou preventivo para as complicações da diabete, tais como retinopatia, nefropatia, neurose, doença cardíaca isquêmica e arteriosclerose; e um agente terapêutico e/ou preventivo para a obesidade. O ativador da glicocinase é caracterizado por conter um derivado de benzimidazol substituído por 2-heteroarila representado pela fórmula geral (I-0): ¢em que X representa carbono ou nitrogênio; X~ 1~, X~ 2~, X~ 3~ e X~ 4~ cada um independentemente representa carbono ou nitrogênio; o anel A representa, por exemplo, um heterociclo aromático nitrogenado de 5 ou 6 membros representado pela fórmula (II): (em que X representa carbono ou nitrogênio); R¬ 1¬ representa arila, etc.; R¬ 2¬ representa hidróxi, etc.; R¬ 3¬ representa -(alquila C~ 1-6~), etc.; R¬ 4¬ representa -(alquila C~ 1-6~), etc.; X~ 5~ representa -O-, etc.; a é 1, 2, ou 3; q é um número inteiro de 0 a 2; e m é um número inteiro de O a 2! ou um sal farmaceuticamente aceitável do derivado.
BRPI0418212-0A 2003-12-29 2004-12-28 composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade BRPI0418212A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003436992 2003-12-29
JP2004235696 2004-08-13
PCT/JP2004/019843 WO2005063738A1 (ja) 2003-12-29 2004-12-28 新規２－へテロアリール置換ベンズイミダゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI0418212A true BRPI0418212A (pt) 2007-04-27

Family

ID=34742165

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418212-0A BRPI0418212A (pt) 2003-12-29 2004-12-28 composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade

Country Status (15)

Country Link
US (1) US7728025B2 (pt)
EP (1) EP1702919B1 (pt)
JP (1) JP4707560B2 (pt)
KR (1) KR20060105872A (pt)
AU (1) AU2004309287B2 (pt)
BR (1) BRPI0418212A (pt)
CA (1) CA2553160C (pt)
EC (1) ECSP066682A (pt)
IL (1) IL176451A0 (pt)
IS (1) IS8509A (pt)
MA (1) MA28336A1 (pt)
NO (1) NO20063475L (pt)
NZ (1) NZ548128A (pt)
RU (1) RU2329261C2 (pt)
WO (1) WO2005063738A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
WO2006040527A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
KR20070083939A (ko) 2004-11-02 2007-08-24 반유 세이야꾸 가부시끼가이샤 아릴옥시 치환된 벤즈이미다졸 유도체
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ575514A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
AU2006267338B2 (en) * 2005-07-13 2012-08-16 Msd K.K. Heterocycle-substituted benzimidazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009508832A (ja) * 2005-09-16 2009-03-05 アストラゼネカ アクチボラグ グルコキナーゼ活性化剤としてのヘテロ二環式化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080293775A1 (en) * 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
JP5280862B2 (ja) 2006-01-23 2013-09-04 アムジエン・インコーポレーテツド オーロラキナーゼ調節剤および使用方法
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
ES2654847T3 (es) 2006-04-19 2018-02-15 Novartis Ag Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
BRPI0721143A2 (pt) 2006-12-21 2014-03-11 Astrazeneca Ab Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
EP2221301B1 (en) 2007-11-12 2014-06-04 Msd K.K. Heteroaryloxy quinazoline derivative
MX2010008637A (es) * 2008-02-06 2010-08-30 Daiichi Sankyo Co Ltd Derivado de fenilpirrol novedoso.
WO2009134754A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
US8592428B2 (en) 2008-08-15 2013-11-26 Msd K. K. Acetyl pyrrolidinyl indole derivative
CA2734981A1 (en) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co., Ltd. Oxotetrahydrofuran-2-yl-benzimidazole derivative
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR077328A1 (es) 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
MX2012005248A (es) 2009-11-06 2012-06-14 Univ Vanderbilt Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica.
BR112012013195A2 (pt) * 2009-12-04 2016-08-09 Nissan Chemical Ind Ltd compostos de 2-piridona.
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SG181431A1 (en) 2009-12-31 2012-07-30 Novartis Ag Pyrazine derivatives and their use in the treatment of neurological disorders
CN102666507B (zh) 2010-07-13 2014-09-17 诺华股份有限公司 噁嗪衍生物及其在治疗神经病症中的用途
MX2013008111A (es) 2011-01-12 2013-10-30 Novartis Ag Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos.
BR112014009910B1 (pt) 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica
EP3043784B9 (en) 2013-09-09 2019-11-20 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US10947239B2 (en) 2015-11-02 2021-03-16 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
BR112019008163A2 (pt) 2016-11-02 2019-07-09 Janssen Pharmaceutica Nv compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
ES2912264T3 (es) 2016-11-02 2022-05-25 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
EA039788B1 (ru) 2016-11-02 2022-03-14 Янссен Фармацевтика Нв Производные [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
EP4367112A1 (en) 2021-07-09 2024-05-15 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134354C (pt) 1963-05-23
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
EP0726260A1 (en) 1995-02-08 1996-08-14 American Cyanamid Company Herbicidal (1,2,4)thiadiazoles
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
AU764184B2 (en) * 1998-01-23 2003-08-14 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
JP2000026430A (ja) * 1998-07-02 2000-01-25 Taisho Pharmaceut Co Ltd ２、５、６−置換ベンズイミダゾール化合物誘導体
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
NZ540791A (en) * 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
KR20070083939A (ko) * 2004-11-02 2007-08-24 반유 세이야꾸 가부시끼가이샤 아릴옥시 치환된 벤즈이미다졸 유도체
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
RU2329261C2 (ru) 2008-07-20
JPWO2005063738A1 (ja) 2007-07-19
EP1702919B1 (en) 2012-05-30
CA2553160A1 (en) 2005-07-14
CA2553160C (en) 2010-09-28
AU2004309287B2 (en) 2008-07-31
RU2006127420A (ru) 2008-02-10
AU2004309287A1 (en) 2005-07-14
EP1702919A4 (en) 2008-11-12
ECSP066682A (es) 2006-10-25
MA28336A1 (fr) 2006-12-01
IS8509A (is) 2006-06-15
IL176451A0 (en) 2006-10-05
JP4707560B2 (ja) 2011-06-22
KR20060105872A (ko) 2006-10-11
WO2005063738A1 (ja) 2005-07-14
US20080070928A1 (en) 2008-03-20
NO20063475L (no) 2006-09-28
NZ548128A (en) 2010-05-28
US7728025B2 (en) 2010-06-01
EP1702919A1 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
BRPI0418212A (pt) composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
CN1681495B (zh) 用于治疗过度增生性疾病的组合物
BRPI0513824A (pt) derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes
BRPI0513752A (pt) derivado de ciclohexano, pró-droga do mesmo e sal do mesmo e agente terapêutico contendo o mesmo para diabetes
BR0116607A (pt) Derivados de glicopiranosiloxipirazol e uso dos mesmos em medicamentos
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
BR0311331A (pt) Composto, seu uso, medicamento, composição farmacêutica, método para prevenir ou tratar uma doença contra a qual um controle da expressão do gene é eficaz, método para prevenir ou tratar uma doença contra a qual a supressão da produção de vegf é eficaz, e método para prevenir ou tratar uma doença contra a qual uma inibição da angiogênese é eficaz
BRPI0409136A (pt) composto heteroaromático pentacìclico e uso medicinal do mesmo
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
BR0310006A (pt) Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
PL375701A1 (en) Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
BR0109323A (pt) Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados
DE602005014341D1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
BRPI0508243A (pt) derivados de anéis fundidos nitrogenados, composições medicinais contendo os derivados e uso destas como drogas
CA2613303A1 (en) An oxime derivative for use as a glucokinase activator
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
BRPI0514509A (pt) uso de composto n-aril diazaespiracìclicos no tratamento de dependência
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
CA2415577A1 (en) Use of cox-2 inhibitors for preventing immunodeficiency
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.